Sign In
8 Dec 2008 11:15
8th December 2008
ReGen Therapeutics Plc <AIM: RGT, OTCQX: REGUY> Announces Publication of a Book on the Effects of Zolpidem Following Brain Damage.
ReGen Therapeutics Plc ("ReGen" or the "Company") announces that its scientific adviser Dr Ralf Clauss will shortly publish a book on the effects of zolpidem following brain damage.
Entitled 'Hope in Brain Damage' (ISBN 97895594093), the book is scheduled for publication on 11th January 2009 and is already available to order at large bookstores, including Waterstones, Amazon, Blackwell and WH Smith.
'Hope in Brain Damage' is the fascinating story of Louis Viljoen, a young man categorized as being in a vegetative state after a road accident, but who regained consciousness, three years later following treatment with zolpidem. The story follows Louis in his progress, since doctors treating him in South Africa discovered that the drug appeared to have a dramatic and sustainable effect in reversing cognitive and functional debilities associated with brain damage.
The book has been written by Dr Ralf Clauss, who developed the treatment in collaboration with Dr Wally Nel of the Walko Medical Centre in Springs, South Africa. The use of zolpidem in various brain damage conditions including stroke and birth injury is described, ethical considerations are raised and new therapies for patients with brain damage are discussed.
ReGen acquired the rights to the further development of this potential new use for zolpidem from Sciencom Ltd in 2006. Percy Lomax, Chairman & Chief Executive of ReGen commented:-
"The publication of this book is a tribute to the hard work and dedication of its author and his co-workers. The discovery of this alternative use of zolpidem for a condition that is both largely untreatable and a terrible drain on the families of affected individuals was remarkable and is something that should be celebrated. We are confident that the wider circulation of this fascinating "inside story" of Louis Viljoen's progress will bring hope to everyone with an interest in this area".
For further information:
Percy LomaxReGen Therapeutics PlcTel: 020 7153 4920
Roland Cornish/Felicity Geidt
Beaumont Cornish Limited
Tel: 020 7628 3396
David Scott/Nick Bealer
Alexander David
Tel: 020 7448 9820
Adrian Duffield/Jon Davies
College Hill Associates
Tel: 020 7457 2020
Follow the stocks
